Appel, I.M.

Bierings, M.B.

Boer, A. de

Maagdenberg, H.

Maitland-van der Zee, A.H.

Meer, F.J.M. van der

Ommen, C.H. van

Tamminga, R.Y.J.

Essentials The knowledge of quality and safety of acenocoumarol and phenprocoumon use in children is limited. We used data from a multicenter retrospective follow-up study in children in the Netherlands. The quality of anticoagulation control in the first month of use was low, but improved thereafter. No thromboembolic events occurred, however bleeding events occurred in 1-3 out of 10 patients. SUMMARY: Background The use of vitamin-K antagonists in pediatric patients is rare and information on the quality and safety of treatment with acenocoumarol and phenprocoumon is limited. Objectives To assess the quality, safety and effectiveness during the first year of acenocoumarol and phenprocoumon treatment in pediatric patients in the Netherlands. Methods The Children Anticoagulation and Pharmacogenetics Study (CAPS) was designed as a multicenter retrospective follow-up study. Patients who used acenocoumarol or phenprocoumon at an age of ≤ 18 years, were selected from four pediatric hospitals and one anticoagulation clinic in the Netherlands. The quality of treatment was assessed by calculating the percentage of time in therapeutic INR range (TTR) for the first month and for every 3 months of use during the first year of treatment. Effectiveness and safety were assessed by the number of thromboembolic and bleeding events. Results In total, 213 patients participated, of whom 187 (155 acenocoumarol; 32 phenprocoumon) were included in this analysis. The mean TTR was 47.0% and 51.4% in the first month of use for acenocoumarol and phenprocoumon, respectively. After the first 3 months the mean TTR for both VKAs was above 64%. In 14.6% (acenocoumarol) and 31.3% (phenprocoumon) of the patients a bleeding event occurred during the first year of treatment; no thromboembolic events were reported. Conclusions The quality of anticoagulation treatment was low during the first month of use and leaves room for improvement. After the first month it increased to an acceptable level. However, bleeding events occurred frequently during the first year

Maagdenberg, Hedy

Bierings, M. B.

van Ommen, C. H.

van der Meer, F. J.M.

Appel, Inge M

Tamminga, Rienk Y J

de Boer, A.

Maitland-van der Zee, Anke H.

NARCIS 

Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort

Background: The use of vitamin-K antagonists in pediatric patients is rare and information on the quality and safety of treatment with acenocoumarol and phenprocoumon is limited. Objectives: To assess the quality, safety and effectiveness during the first year of acenocoumarol and phenprocoumon treatment in pediatric patients in the Netherlands. Methods: The Children Anticoagulation and Pharmacogenetics Study (CAPS) was designed as a multicenter retrospective follow-up study. Patients who used acenocoumarol or phenprocoumon at an age of <= 18 years, were selected from four pediatric hospitals and one anticoagulation clinic in the Netherlands. The quality of treatment was assessed by calculating the percentage of time in therapeutic INR range (TTR) for the first month and for every 3 months of use during the first year of treatment. Effectiveness and safety were assessed by the number of thromboembolic and bleeding events. Results: In total, 213 patients participated, of whom 187 (155 acenocoumarol; 32 phenprocoumon) were included in this analysis. The mean TTR was 47.0% and 51.4% in the first month of use for acenocoumarol and phenprocoumon, respectively. After the first 3 months the mean TTR for both VKAs was above 64%. In 14.6% (acenocoumarol) and 31.3% (phenprocoumon) of the patients a bleeding event occurred during the first year of treatment; no thromboembolic events were reported. Conclusions: The quality of anticoagulation treatment was low during the first month of use and leaves room for improvement. After the first month it increased to an acceptable level. However, bleeding events occurred frequently during the first yea

van der Meer, F. J. M.

Appel, I. M.

Tamminga, R. Y. J.

Maitland-van der Zee, A. H.

BACKGROUND: The use of vitamin-K antagonists in pediatric patients is rare and information on quality and safety of the treatment with acenocoumarol and phenprocoumon is limited. OBJECTIVES: To assess the quality, safety and effectiveness during the first year of acenocoumarol and phenprocoumon treatment in pediatric patients in the Netherlands. METHODS: The Children Anticoagulation and Pharmacogenetics Study (CAPS) was designed as a multicenter retrospective follow-up study. Patients, who used acenocoumarol or phenprocoumon at an age of ≤18 years, were selected in four pediatric hospitals and one anticoagulation clinic in the Netherlands. The quality of treatment was assessed by calculating the percentage of time in therapeutic INR range (TTR) for the first month and for every three months of use during the first year of treatment. Effectiveness and safety were assessed by the number of thromboembolic and bleeding events. RESULTS: In total 213 patients participated, of whom 187 (155 acenocoumarol; 32 phenprocoumon) patients were included in this analysis. The mean TTR was 47.0% and 51.4% in the first month of use, for acenocoumarol and phenprocoumon, respectively. After the first 3 months the mean TTR was for both VKAs above 64%. In 14.6% (acenocoumarol) and 31.3% (phenprocoumon) of the patients a bleeding event occurred during the first year of treatment, no thrombotic events were reported. CONCLUSIONS: The quality of anticoagulation treatment was low during the first month of use and leaves room for improvement. After the first month it increased to an acceptable level. However, bleeding events occurred frequently during the first year. This article is protected by copyright. All rights reserved

Bierings, Marc B

van Ommen, C Heleen

van der Meer, Felix J M

de Boer, Anthonius

Maitland-van der Zee, Anke H

Leiden University Scholary Publications

University of Groningen

BACKGROUND: The use of vitamin-K antagonists in pediatric patients is rare and information on quality and safety of the treatment with acenocoumarol and phenprocoumon is limited.OBJECTIVES: To assess the quality, safety and effectiveness during the first year of acenocoumarol and phenprocoumon treatment in pediatric patients in the Netherlands.METHODS: The Children Anticoagulation and Pharmacogenetics Study (CAPS) was designed as a multicenter retrospective follow-up study. Patients, who used acenocoumarol or phenprocoumon at an age of ≤18 years, were selected in four pediatric hospitals and one anticoagulation clinic in the Netherlands. The quality of treatment was assessed by calculating the percentage of time in therapeutic INR range (TTR) for the first month and for every three months of use during the first year of treatment. Effectiveness and safety were assessed by the number of thromboembolic and bleeding events.RESULTS: In total 213 patients participated, of whom 187 (155 acenocoumarol; 32 phenprocoumon) patients were included in this analysis. The mean TTR was 47.0% and 51.4% in the first month of use, for acenocoumarol and phenprocoumon, respectively. After the first 3 months the mean TTR was for both VKAs above 64%. In 14.6% (acenocoumarol) and 31.3% (phenprocoumon) of the patients a bleeding event occurred during the first year of treatment, no thrombotic events were reported.CONCLUSIONS: The quality of anticoagulation treatment was low during the first month of use and leaves room for improvement. After the first month it increased to an acceptable level. However, bleeding events occurred frequently during the first year. This article is protected by copyright. All rights reserved.</p

Terrace Review, May, 28, 1986

Abstract

Similar works

Full text

Available Versions

NARCIS

NARCIS

NARCIS

Leiden University Scholary Publications

University of Groningen

Dissertations of the University of Groningen

Arca British Columbia's network of post-secondary digital repositories

ARTS repository - University of Groningen

NARCIS

Dissertations of the University of Groningen